Africa has a wealth of indigenous plant species, but has not been as successful as India and China at commercializing them as nutraceuticals, one South African firm trying to spread the word about the continent’s natural ingredients tells Elaine Watson
Norwegian firm Calanus AS has applied to the UK Food Standards Agency for European Union novel foods approval to market an omega-3 oil derived from the miniature North Atlantic Ocean shrimp, Calanus finmarchicus.
GNC, Cellucor Sports Nutrition and others have been accused of misleading consumers over the source, regulatory status and safety of the controversial stimulant DMAA (1,3 Dimethylamylamine) in a new class action lawsuit filed in California.
Experts in helping firms navigate the GRAS (generally recognized as safe) process say the American Heart Association (AHA) made some valid points in its recent attack on GRAS, but argue the system is actually working pretty well.
There are serious weaknesses in the system that allows firms to self-affirm the safety of foods without the approval or knowledge of the Food and Drug Administration (FDA), according to the American Heart Association (AHA).
Martek’s new algal EPA/DHA blend - the ‘fishless fish oil’ - is gaining momentum in the market with recent launches including Schiff’s MegaRed Plant-Omega supplements and Darigold Omega-3 2% milk.
The United Natural Products Alliance (UNPA) says it agrees with the AHPA that supplement makers should not label the stimulant DMAA (1,3-Dimethylamylamine) as geranium oil or as any part of the geranium plant.
Trade in sports products containing the controversial stimulant DMAA (methylhexaneamine/1,3-dimethylamylamine) is illegal in the European Union, and should be brought to an immediate halt by EU and member state authorities, according to the Council for...
GNC has weighed into the debate over the stimulant DMAA (1,3-Dimethylamylamine) following the recall of DMAA-containing products from stores on military bases while the Department of Defense conducts a probe into its safety.
The Food and Drug Administration (FDA) has weighed into the debate over the stimulant DMAA (1,3-Dimethylamylamine, also known as methylhexaneamine or MHA), which has garnered more bad press in recent weeks.
Those hoping the Food and Drug Administration (FDA) is preparing for a major climb down on its draft guidance on new dietary ingredients (NDIs) will draw little comfort from comments made by the agency's supplements chief yesterday.
An authoritative new guide to 23+solvents used in the production of botanical extracts for dietary ingredients could help inform the debate on ‘chemical alteration’ at the heart of the FDA’s draft guidance on new dietary ingredients (NDIs), says the American...
Jarrow Formulas is still waiting for a “substantive response” from the Food and Drug Administration (FDA) to a Freedom of Information Act (FOIA) request submitted more than two months ago about the FDA’s draft guidance on New Dietary Ingredients (NDIs).
The chief architect of the 1994 Dietary Supplement Health and Education Act (DSHEA) does not believe the Food and Drug Administration’s (FDA’s) draft guidance on new dietary ingredients (NDIs) is consistent with the legislation he co-authored, his office...
The FDA will be “laughed out of court” if it tries to defend enforcement action against supplement manufacturers based on the argument that new dietary ingredient (NDI) notifications should apply to finished products, not ingredients, one industry leader...
A range of options – “judicial, administrative and Congressional” – is being explored by the dietary supplements industry should the FDA prove unwilling to make substantial changes to its controversial draft guidance on new dietary ingredients (NDIs).
If sufficient pressure is exerted on key members of Congress, it is not beyond the realms of possibility that the FDA might suspend its draft guidance on NDIs (new dietary ingredients) or even withdraw it altogether, according to food law attorney Jonathan...
If stakeholders are granted more time to respond to the FDA’s draft guidance on new dietary ingredients (NDIs), it should be possible to reach a compromise that will satisfy regulators without devastating the dietary supplements industry, trade associations...
The FDA should calculate how much complying with its guidance on new dietary ingredients (NDIs) will cost before forcing the supplements industry to embark on a “giant paperwork exercise” that will not make consumers any safer, according to the first...
A New Orleans-based biotech firm on a mission to commercialize “novel evidence-based prebiotic products” is aiming to bring its first products to market next year.
A Beverly Hills-based biotech firm is planning to launch a series of supplements and functional foods containing ergothioneine, an antioxidant it claims has “unparalleled” benefits that has hidden its light under a bushel for almost 100 years.
Nicotinamide riboside (NR) - the latest addition to ChromaDex’s bioactive ingredients stable – will follow a similar development path to pterostilbene, a compound found in blueberries it has synthesized to create a branded ingredient called pTeroPure.
A new player is poised to enter the vegetarian omega-3 market with a production process it claims will enable it to make the long chain fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) from algae at a fraction of the cost of rivals.
There is “no logic” to the FDA’s insistence that NDI (new dietary ingredient) notifications are applicable only to the specific manufacturer that submits them, according to one leading food law attorney.
The argument that the FDA has overstepped its legal remit in its draft guidance on new dietary ingredients (NDIs) is gaining ground, with one food law expert claiming the FDA is “trying to dismantle” the legislation it is supposed to be clarifying.
Many dietary ingredients used in supplements today bear little resemblance to ingredients that were assumed to be ‘grandfathered in’ post the 1994 Dietary Supplements Health and Education Act, making a fresh safety analysis eminently reasonable if extraction...
The American Botanical Council (ABC) has weighed into the debate over the Food and Drug Administration’s (FDA’s) draft guidance document on new dietary ingredient (NDI) notifications.
A leading food law expert and the Food and Drug Administration’s (FDA’s) dietary supplements chief agreed to disagree over several key aspects of the FDA’s draft guidance on new dietary ingredients (NDIs) during a spirited conference call with stakeholders...
Big interview: Daniel Fabricant, Food and Drug Administration (FDA)
The trade can rail against the Food and Drug Administration's new dietary ingredient (NDI) guidance as much as it likes, but it cannot honestly pretend to be shocked or even surprised by it, according to the man in charge of the FDA’s dietary supplements...
While many stakeholders warn that the FDA’s controversial NDI draft guidance will stifle innovation and bury the supplements trade (and the FDA itself) under a hellish mountain of paperwork, they cannot pretend they didn’t see it coming, Herbalife’s Vasilios...
While many stakeholders seem to believe that the Food and Drug Administration’s (FDA’s) controversial draft guidance document on NDI (new dietary ingredient) notifications could spell Armageddon for the supplements trade, this is actually quite unlikely,...
The amount of safety data the FDA now says it requires to prove new ingredients in supplements are safe goes well beyond what Congress envisaged when it ratified DSHEA and establishes a process “ominously like the one for new food additives”, the Council...
If the Food and Drug Administration (FDA) does not revise its draft guidance on new dietary ingredients (NDIs) for supplements to reflect industry concerns, the trade might be stuck between a rock and a hard place, admit lawyers.
The limited nature of many toxicity studies into engineered nanoparticles used in the food and dietary supplements industry makes it very difficult to draw firm conclusions about their safety, according to one expert in the field.
There could be serious consequences for industry if the Food and Drug Administration (FDA) decides to start enforcing guidance clarifying the legal dividing line between liquid dietary supplements and conventional beverages, an expert has warned.
Last week the Food and Drug Administration (FDA) denied a petition that sought to have a synthetically manufactured algae extract called homotaurine classified as a new dietary ingredient (NDI).
Italian supplier Gnosis Bioresearch has won New Dietary Ingredient (NDI) approval from the Food and Drug Administration for a synthetic folate salt form.
The Food and Drug Administration has issued a letter of no objection to Burcon NutraScience Corporation for its canola protein extracts, an important milestone for further development.
Ingredient firm DSM says its branded genistein ingredient marketed for menopause and bone benefits could appear in foods sold in the US within the next 12 months, following strong interest generated by a recent GRAS affirmation.
Two Californian ingredient suppliers this week announced that their antioxidant grape extract ingredients have received GRAS affirmation, opening up their use in food and beverage products marketed for heart health.
Ethical Naturals Inc (ENI) has received GRAS status for its L-Theanine ingredient, which the firm says will help its uptake in the world of functional beverages.
Cognis, global nutritional ingredients and specialty chemicals supplier, has achieved GRAS (Generally Recognized As Safe) status for its tabletting agent Texapon K 12 P PH, a pharmaceutical grade sodium lauryl sulfate (SLS).
The FDA has told Ovos Natural Health it needs more time to process the Canadian biotech firm’s petition to have its brain health offering, homotaurine, accepted as a new dietary ingredient (NDI).
A new selenium-enriched garlic product from Sabinsa is now available for inclusion in dietary supplement formulations in the United States after the Food and Drug Administration filed New Dietary Ingredient notification for the company’s latest offering.
Global CLA (conjugated linoleic acid) leader, Cognis, has won a category-first novel foods approval to use its weight management ingredient in Chinese functional foods and dietary supplements.
Baobab fruit pulp has been given the green light of approval for use in some food and drink applications, with the US FDA signing off GRAS status for the vitamin C-rich ingredient.
Herbal extract supplier Sabinsa has received GRAS status for its curcumin antioxidant ingredient, opening up its use in certain food and beverage applications in the US, including baked goods, snacks and dairy products.
Minneapolis-based Bioenergy tells Lorraine Heller about the application areas opened up for its D-Ribose energy ingredient, following its determination as Generally Recognized as Safe (GRAS) for use in foods and beverages.
Ingredient firm Cypress Systems has received FDA-reviewed GRAS status for its selenium yeast product, opening up the use of the ingredient in foods and beverages targeting a range of health conditions, including cancer risk reduction.
